Skip to content
DataLookout
Menu

NCT06834438

Gene Therapy for Neurofibromatosis Type 2 (NF2) With ST002

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words Show 5 more changesShow less
    • Completed without a posted recruiting period
    • Primary completion date changed from estimate of Feb 1, 2026 to Apr 8, 2026
    • Study completion date changed from estimate of Feb 1, 2027 to Apr 13, 2026
    • Start date changed from estimate of Feb 15, 2025 to Mar 19, 2025
    • Secondary endpoints: details revised at 1 of 2 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety evaluation
Timeframe: From baseline to Week 24 after administration

Secondary (1)

Efficacy evaluation

Arms and interventions

ST002Experimental

Subjects will receive with a single multi-point intra-tumoral injection of ST002 from 1x10\^7 to 1x10\^8 TU into the tumor.

Genetic: ST002

Sites

1 site in 1 country

  • Shuhang WangBeijing, Beijing Municipality, China